cas 40794-04-5|| where to buy 4-Chloro-2-methoxy-1-methylbenzene

Nombre del producto:4-Chloro-2-methoxy-1-methylbenzene

IUPAC Name:4-chloro-2-methoxy-1-methylbenzene

Unidad de embalaje	Stock disponible	Precio($)
CM283380-5g	in stock	ƋƋ
CM283380-10g	in stock	ƱƻǕ
CM283380-25g	in stock	Ʊǲȷ
CM283380-100g	in stock	ƋƱɐ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 40794-04-5 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :40794-04-5; Fórmula molecular:C8H9ClO; Punto de fusión:-; Código de sonrisas:CC1=CC=C(Cl)C=C1OC; Densidad:

: Número de catálogo:CM283380; Peso molecular:156.61; Punto de ebullición:204°C at 760 mmHg; Nº Mdl:MFCD07368289; Almacenamiento:Store at 2-8°C.

: Crinecerfont; The New England Journal of Medicine publishes the primary CAHtalyst™ Adult Phase 3 study results of Crinecerfont for the treatment of congenital adrenal hyperplasia (CAH). Classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) is a rare genetic disorder, affected by a lack of cortisol and/or aldosterone. Corticotropin-releasing factor type 1 receptor (CRF1) antagonism is shown to clinically decrease ACTH production and adrenal androgen levels.
Neurocrine's Crinecerfont is an investigational, selective CRF1 antagonist being developed to reduce and control excess adrenocorticotropic hormone (ACTH) and adrenal androgens. The phase 3 study meets primary and important key secondary endpoints, including a significant reduction in androstenedione levels and lowering glucocorticoid dosing.